ID   HBL-100
AC   CVCL_4362
SY   HBL 100; HBL100
DR   BTO; BTO:0004734
DR   CLO; CLO_0003626
DR   EFO; EFO_0001167
DR   CLDB; cl1571
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-TABM-157
DR   ATCC; HTB-124
DR   BioSample; SAMN03152011
DR   BioSample; SAMN03471101
DR   BioSample; SAMN03472914
DR   CCRID; 3111C0001CCC000374
DR   CCRID; 3131C0001000200010
DR   ChEMBL-Cells; CHEMBL3307713
DR   ChEMBL-Targets; CHEMBL614811
DR   CLS; 300178/p775_HBL-100
DR   Cosmic; 687471
DR   Cosmic; 877447
DR   Cosmic; 934533
DR   Cosmic; 979722
DR   Cosmic; 991323
DR   Cosmic; 1010933
DR   Cosmic; 1136364
DR   Cosmic; 1176632
DR   Cosmic; 1434949
DR   Cosmic; 1524348
DR   Cosmic; 1609469
DR   DepMap; ACH-002321
DR   GEO; GSM1053697
DR   LINCS_HMS; 51117
DR   PharmacoDB; HBL100_443_2019
DR   RCB; RCB0460
DR   TOKU-E; 3589
DR   Wikidata; Q54881428
RX   CelloPub=CLPUB00368;
RX   CelloPub=CLPUB00423;
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RX   PubMed=2547730;
RX   PubMed=2995096;
RX   PubMed=6500159;
RX   PubMed=6891286;
RX   PubMed=9671407;
RX   PubMed=12661003;
RX   PubMed=16643607;
RX   PubMed=17157791;
RX   PubMed=20143388;
RX   PubMed=24094812;
RX   PubMed=24176112;
RX   PubMed=25485619;
RX   PubMed=28889351;
CC   Problematic cell line: Misidentified. Presence of a Y chromosome in cell line that was thought to be of female origin (PubMed=16643607; PubMed=20143388). Originally thought to originate from a casein-producing breast cell line. In addition contains SV40 genomic sequence while the cell line was deemed to be spontaneously immortalized.
CC   Part of: GrayJW Breast Cancer Cell Line Panel.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00207.
CC   Characteristics: Contains two copies of the SV40 genome, one complete the other incomplete tandemly integrated in the cell line genome.
CC   Doubling time: 1.5 days (PubMed=9671407); ~40 hours (CLS); 30.21 hours (!Synapse:syn2347014).
CC   Microsatellite instability: Stable (MSS) (PubMed=12661003).
CC   Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Discontinued: ATCC; HTB-124; true.
CC   Discontinued: RCB; RCB0460; true.
ST   Source(s): ATCC; CCRID; CLS; PubMed=25877200; PubMed=28889351
ST   Amelogenin: X,Y (ATCC; CLS; PubMed=11416159)
ST   Amelogenin: X (CCRID; PubMed=25877200; PubMed=28889351)
ST   CSF1PO: 10
ST   D13S317: 12
ST   D16S539: 9,12
ST   D18S51: 16
ST   D19S433: 15
ST   D21S11: 28,30
ST   D2S1338: 18,24
ST   D3S1358: 14,16
ST   D5S818: 11,12
ST   D7S820: 8,12
ST   D8S1179: 12,15
ST   FGA: 25
ST   Penta D: 12
ST   Penta E: 7
ST   TH01: 6,8
ST   TPOX: 8
ST   vWA: 16
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   Age unspecified
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 25
RX   CelloPub=CLPUB00368;
RA   Polanowski F.P., Gaffney E.V., Burke R.E.;
RT   "HBL-100, a cell line established from human breast milk.";
RL   In Vitro 12:328-328(1976).
RX   CelloPub=CLPUB00423;
RA   Morrison B.J.;
RT   "Breast cancer stem cells: tumourspheres and implications for therapy.";
RL   Thesis PhD (2010), Griffith University, Australia.
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RA   Leibovitz A.;
RT   "Cell lines from human breast.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York (1994).
RX   PubMed=2547730; DOI=10.1002/ijc.2910440230;
RA   Saint-Ruf C., Nardeux P.C., Cebrian J., Lacasa M., Lavialle C.,
RA   Cassingena R.;
RT   "Molecular cloning and characterization of endogenous SV40 DNA from
RT   human HBL-100 cells.";
RL   Int. J. Cancer 44:367-372(1989).
RX   PubMed=2995096; DOI=10.1016/0014-4827(85)90238-1;
RA   Caron de Fromentel C., Nardeux P.C., Soussi T., Lavialle C.,
RA   Estrade S., Carloni G., Chandrasekaran K., Cassingena R.;
RT   "Epithelial HBL-100 cell line derived from milk of an apparently
RT   healthy woman harbours SV40 genetic information.";
RL   Exp. Cell Res. 160:83-94(1985).
RX   PubMed=6500159; DOI=10.1159/000163283;
RA   Gershwin M.E., Lentz D., Owens R.B.;
RT   "Relationship between karyotype of tissue culture lines and
RT   tumorigenicity in nude mice.";
RL   Exp. Cell Biol. 52:361-370(1984).
RX   PubMed=6891286; DOI=10.1007/BF00204786;
RA   Gaffney E.V.;
RT   "A cell line (HBL-100) established from human breast milk.";
RL   Cell Tissue Res. 227:563-568(1982).
RX   PubMed=9671407; DOI=10.1038/sj.onc.1201814;
RA   Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.;
RT   "Lack of relationship between CDK activity and G1 cyclin expression in
RT   breast cancer cells.";
RL   Oncogene 16:2865-2878(1998).
RX   PubMed=12661003; DOI=10.1002/gcc.10196;
RA   Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U.,
RA   Santibanez-Koref M.-F., Schlag P.M., Scherneck S.;
RT   "Identification of microsatellite instability and mismatch repair gene
RT   mutations in breast cancer cell lines.";
RL   Genes Chromosomes Cancer 37:29-35(2003).
RX   PubMed=16643607; DOI=10.1111/j.1749-0774.2005.00007.x;
RA   Yoshino K., Iimura E., Saijo K., Iwase S., Fukami K., Ohno T.,
RA   Obata Y., Nakamura Y.;
RT   "Essential role for gene profiling analysis in the authentication of
RT   human cell lines.";
RL   Hum. Cell 19:43-48(2006).
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008;
RA   Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T.,
RA   Clark L., Bayani N., Coppe J.P., Tong F., Speed T., Spellman P.T.,
RA   DeVries S., Lapuk A., Wang N.J., Kuo W.L., Stilwell J.L., Pinkel D.,
RA   Albertson D.G., Waldman F.M., McCormick F., Dickson R.B.,
RA   Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.;
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
RX   PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020;
RA   Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A.,
RA   Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K.,
RA   McCormick F., Gray J.W.;
RT   "Glutamine sensitivity analysis identifies the xCT antiporter as a
RT   common triple-negative breast tumor therapeutic target.";
RL   Cancer Cell 24:450-465(2013).
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y., Mills G.B., Cho R.J.,
RA   Collisson E.A., van't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=28889351; DOI=10.1007/s10549-017-4496-x;
RA   Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L.,
RA   Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E.,
RA   Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J.,
RA   Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E.,
RA   Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F.,
RA   Lakhani S.R.;
RT   "Multidimensional phenotyping of breast cancer cell lines to guide
RT   preclinical research.";
RL   Breast Cancer Res. Treat. 167:289-301(2018).